Reminyl, Galantamine Newswire

Comprehensive Real-Time News Feed for Reminyl, Galantamine (generic).

Results 1 - 12 of 12 in Reminyl, Galantamine (generic)

  1. Why Alzheimer's Drugs Keep FailingRead the original story

    Monday Jul 14 | Scientific American

    Drug candidates have a 99.6 percent failure rate, and poor early detection methods make clinical trials difficult and costly Areas of cell loss are in red on this brain scan of an older person with Alzheimer's disease.

    Comment?

  2. Renewed focus on dementia checked by drug challengesRead the original story w/Photo

    Thursday Jul 3 | Chemistry World

    Efforts to target amyloid protein plaques, thought to be responsible for Alzheimer's disease, have run into trouble Science Photo Library The world needs to tackle head-on the market failures undermining dementia research and drug development, UK Prime Minister David Cameron told a summit of world health and finance leaders in London in ... (more)

    Comment?

  3. The Natural Products Association (NPA) welcomed Devon Powell as its new senior vice presidentRead the original story

    Wednesday Jul 2 | HAPPI/Household & PP Industry

    The Natural Products Association : welcomed Devon Powell as its new senior vice president of member services and chief operating officer .

    Comment?

  4. Kraft Foods Takes on New Vice ChairmanRead the original story

    Jun 6, 2014 | Refrigerated & Frozen Foods

    National Frozen & Refrigerated Foods Association, Harrisburg, Pa . Natalie Markle was added to the newly created position of member communications coordinator, responsible for marketing member resources and events, developing and maintaining an online and social media presence for members and engaging members in NFRA's PR and promotion efforts.

    Comment?

  5. A Randomized, Placebo-Controlled Study Investigating the Nicotinic...Read the original story

    May 14, 2014 | Neuropsychopharmacology

    We'd like to invite you to take part in our annual reader survey. As a thank you for your participation you will have the opportunity to enter a prize draw to win a MacBook Air.

    Comment?

  6. NPA Taps Former FDA ChiefRead the original story

    Jun 3, 2014 | HAPPI/Household & PP Industry

    The Natural Products Association : hired Corey Hilmas, MD, Ph.D., to serve as its new senior vice president of scientific and regulatory affairs.

    Comment?

  7. slider_May2014_TorosyanRead the original story

    May 9, 2014 | Applied Radiology

    Alzheimer's disease is the most common neurodegenerative disorder, and cases of AD continue to rise, posing a significant clinical and financial challenge for the upcoming years.

    Comment?

  8. Pharmacological Dissociation of Novelty Responses in the Human BrainRead the original story

    Apr 7, 2014 | Cerebral Cortex

    Address correspondence to Dr Nico Bunzeck, Department of Systems Neuroscience, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.

    Comment?

  9. Impaired working memory by repeated neonatal MK-801 treatment is...Read the original story

    Mar 13, 2014 | CiteULike

    European journal of pharmacology , Vol. 725 , pp. 32-39, doi:10.1016/j.ejphar.2014.01.007 Early life blockade of the NMDA receptor by using MK-801, a non-competitive NMDA receptor antagonist, induces behavioral changes that mimic several features of schizophrenia.

    Comment?

  10. Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex.Read the original story

    Mar 13, 2014 | CiteULike

    The tryptophan metabolite kynurenic acid is an endogenous antagonist of the I 7 nicotinic acetylcholine receptor and, at higher concentrations, inhibits ionotropic glutamate receptors.

    Comment?

  11. Impaired working memory by repeated neonatal MK-801 treatment is...Read the original story

    Feb 11, 2014 | CiteULike

    Early life blockade of the NMDA receptor by using MK-801, a non-competitive NMDA receptor antagonist, induces behavioral changes that mimic several features of schizophrenia.

    Comment?

  12. Alzheimer's Disease Therapeutics Market to 2019 - Early Stage...Read the original story

    Jan 22, 2014 | Sys-Con Media

    Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation Summary GBI Research has released its pharmaceuticals report, "Alzheimer's Disease Therapeutics Market to 2019 - Early Stage Innovation Points to Disease Modifying Therapies and Market Transformation".

    Comment?